Key Highlights

● ZeroStack Corp., formerly cannabis-and-pharma distributor Flora Growth, disclosed new German pharmaceutical purchase orders worth up to $14.7 million just as it closed a transaction giving it roughly a fifth of the 0G cryptocurrency's total supply.

● ZeroStack's fiscal 2025 annual report disclosed a net loss of $119.7 million and an accumulated deficit of $277.8 million, alongside a going-concern risk factor.

● A roughly $12 million market-cap company now holds a treasury concentrated in a single, thinly traded cryptocurrency whose price could swing sharply, adding a new layer of volatility risk.

● Investors should watch for completion and terms of the non-dilutive financing meant to fund the $14.7 million Phatebo inventory orders.

ZeroStack Corp., the Toronto-based company formerly known as Flora Growth Corp., told investors on July 20, 2026 that its German pharmaceutical subsidiary had booked purchase orders worth up to roughly $14.7 million, even as the parent completed a far larger pivot: absorbing more than 142 million units of a cryptocurrency called 0G onto its balance sheet. The disclosures underscore a company now straddling two very different businesses, a modest, contracted European pharma-distribution operation and a concentrated, volatile digital-asset treasury.

What happened

In a July 20, 2026 release, ZeroStack said its German subsidiary, Phatebo GmbH, secured purchase orders from two unnamed pharmaceutical companies for up to approximately $14.7 million (about €12.9 million) of inventory, a figure first flagged in a related release on July 9. The company said it intends to fund the resulting inventory purchases through "non-dilutive forms of financing," explicitly ruling out new equity issuance for that purpose, while cautioning there is no assurance such financing will be secured on acceptable terms. The same release confirmed shareholders approved all eight proposals at the 2026 annual and special meeting, including a staggered board, reappointment of auditor Davidson & Company LLP, and authorization to redomicile from Ontario to Texas. It also confirmed the closing of a previously announced transaction in which investors contributed 142,232,948 Zero Gravity (0G) blockchain tokens to a newly formed Texas Blocker Corp. in exchange for 9,104,614 shares, which were then exchanged one-for-one for ZeroStack common shares, making Texas Blocker a wholly owned subsidiary.

Why the development matters

The two disclosures capture the split identity ZeroStack has adopted since rebranding from Flora Growth in January 2026. The Phatebo order flow is a rare data point suggesting the legacy pharmaceutical business still generates real commercial demand, useful validation given the company's narrative has increasingly centered on digital assets. The token transaction closing alongside it is far larger in scale: ZeroStack has said it expects to hold approximately 21% of the total 0G token supply following the exchange, one of the largest concentrated positions in the 0G ecosystem. For investors, the juxtaposition matters because management is trying to fund working-capital needs without further dilution, even as the company's overall value proposition grows more dependent on the price and liquidity of a single, thinly traded cryptocurrency.

Company and product background

Flora Growth Corp. began as a Canadian cannabis-products company that expanded into pharmaceutical distribution in December 2022 by acquiring Franchise Global Health, whose operating subsidiary, Phatebo GmbH, distributes pharmaceutical and medical-cannabis products in Germany. Facing prolonged Nasdaq minimum-bid-price problems, the company executed a 1-for-39 reverse stock split effective August 2025 and divested its legacy hemp and cannabis operations that September to extinguish debt. After board and shareholder approval in late 2025, the rebrand to ZeroStack Corp. took legal effect January 29, 2026, alongside a strategic focus described as "AI-focused asset management" built around 0G, a blockchain protocol marketed for decentralized AI infrastructure. On March 31, 2026, ZeroStack announced the $107 million token-for-equity financing described above, simultaneously eliminating a 0G-denominated convertible note held by Zero Gravity Labs Inc., a related party whose chief executive, Michael Heinrich, is ZeroStack's Executive Chairman. That transaction closed in July 2026. The company has also reported earning 0G tokens through staking, citing roughly 3.2 million cumulative tokens at an approximate 22% annualized yield as of early March 2026. Near-term milestones include completing the Texas redomicile and fulfilling the Phatebo orders.

Financial position

ZeroStack's fiscal 2025 annual report disclosed a net loss of $119.7 million and an accumulated deficit of $277.8 million, alongside a going-concern risk factor tied to the company's "ability to continue as a going concern absent access to sources of liquidity." The company raised roughly $14.6 million through 2025 private placements. Trailing-twelve-month revenue, driven largely by Phatebo, has been reported around $35.7 million, against a diluted loss per share near $43.49, a figure distorted by the 2025 reverse split and non-cash items tied to the digital-asset transactions. As of late July 2026, shares outstanding stood at roughly 2.4 million, with the stock near $5.10 and a market capitalization of $12.1 million, a valuation that appears to reflect market uncertainty over how the 0G holdings should be valued against such a small public float. Given the going-concern disclosure and unsecured financing for the new pharma orders, any cash-runway estimate should be treated as highly uncertain absent a fresher balance-sheet update.

Bull case

Supporters point to a company diversifying its value drivers: a contracted, revenue-generating European distribution business winning new orders without further equity issuance, paired with an outsized position, reportedly around a fifth of total supply, in an emerging AI-infrastructure token generating double-digit staking yields. Eliminating the 0G-denominated convertible note removed a debt overhang, and management frames ZeroStack as the first Nasdaq-listed, AI-focused asset-management vehicle of its kind, positioning that could draw specialized investors if the underlying token gains broader adoption.

Risk case

The risks are substantial. A roughly $12 million market-cap company now holds a treasury concentrated in a single, thinly traded cryptocurrency whose price could swing sharply, and unwinding a stake equal to a fifth of that token's supply would carry obvious liquidity risk. The going-concern language in the 2025 10-K has not been formally retracted, and financing for the newly won pharma orders is not yet secured. Related-party dynamics, given the Executive Chairman's simultaneous role at Zero Gravity Labs, warrant scrutiny. A history of Nasdaq compliance problems and a 1-for-39 reverse split within the past year point to a difficult capital-markets track record, and the pending Ontario-to-Texas redomicile adds legal and administrative uncertainty atop an already complex dual-business structure.

What investors should watch next

Investors should track: completion and terms of the non-dilutive financing meant to fund the $14.7 million Phatebo inventory orders; finalization of the Ontario-to-Texas redomicile; the market value and staking performance of ZeroStack's 0G treasury in coming quarterly disclosures; the next 10-Q for updated cash, burn rate, and going-concern language; and any further Nasdaq listing-compliance notices.

Conclusion

ZeroStack's latest disclosures capture a company mid-reinvention, retaining a real, order-generating pharmaceutical distribution business in Germany while betting its balance sheet increasingly on a concentrated cryptocurrency position tied to decentralized AI infrastructure. The pharma orders offer modest, verifiable commercial traction; the token treasury offers scale but also volatility that is difficult to independently value. With a going-concern disclosure still on the books and financing for near-term inventory needs unresolved, the story remains in transition, and investors will need subsequent filings to judge whether the pivot is stabilizing the company or adding a new layer of risk.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.